Shenzhen YHLO Biotech (688575) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose 11.04% YoY to RMB 1.429bn; attributable net income increased 137.58% to RMB 143.55m, supported by higher reagent sales, improved margins and lower fair-value losses.

• Q3 revenue grew 13.07% YoY and 10.33% QoQ to RMB 540.79m; attributable net income rose 114.97% YoY and 40.70% QoQ to RMB 73.42m.

Financial highlights

• 9M total profit was RMB 160.26m, up 148.55% YoY; Q3 total profit was RMB 85.29m, up 105.27%.

• Adjusted for non-recurring items, attributable net income was RMB 152.02m for 9M, up 50.66%, and RMB 78.56m in Q3, up 54.45%.

• 9M operating cash flow reached RMB 381.21m, up 486.60% YoY, reflecting revenue growth, higher cash receipts and lower payments for goods and services.

• Period-end total assets were RMB 4.338bn, up 1.15% from year-end 2025; parent-attributable equity was RMB 2.824bn, up 4.72%.

Outlook and guidance

• Cardiovascular chemiluminescence reagent growth is viewed as a potential second growth driver; 9M sales rose 56.80% YoY and Q3 sales rose 70.36%.

• Microfluidics cardiac-marker products entered a substantive commercialization phase after registration approvals for six reagent products and two instruments.